Strong immune response produced by Johnson & Johnson COVID-19 vaccine in early trial
Image Credit: Shortpedia
According to the early result reports, a strong immune response against the novel coronavirus was produced by a single dose of Johnson & Johnson's Covid-19 vaccine in an early-to-mid stage clinical trial. The vaccine named Ad26.COV2.S was equally well-tolerated at two different doses. In comparison to Moderna Inc and Pfizer Inc, Johnson & Johnson is moving ahead with a single dose approach, that may be easy to distribute.